Common Contracts
7 similar Joint Filing Agreement contracts by Biotechnology Value Fund L P
JOINT FILING AGREEMENTJoint Filing Agreement • December 27th, 2019 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated December 26, 2019 (including amendments thereto) with respect to the shares of Common Stock, $0.001 par value per share, of Five Prime Therapeutics, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • March 15th, 2019 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated March 15, 2019 (including amendments thereto) with respect to the shares of Common Stock $0.001 par value, of OncoMed Pharmaceuticals, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • February 1st, 2019 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated February 1, 2019 (including amendments thereto) with respect to the shares of Common Stock $0.01 par value, of Vical Incorporated. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • July 19th, 2018 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated July 18, 2018 (including amendments thereto) with respect to the Ordinary Shares, nominal value €0.10 per share, of ERYTECH Pharma S.A. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • April 12th, 2018 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated April 12, 2018 (including amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Infinity Pharmaceuticals, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • January 14th, 2016 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated January 13, 2016 (including amendments thereto) with respect to the shares of Common Stock, no par value, of CTI BioPharma Corp. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • December 11th, 2015 • Biotechnology Value Fund L P • Investment advice
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated December 10, 2015 (including amendments thereto) with respect to the shares of Common Stock, no par value, of CTI BioPharma Corp. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
